1,720,967 research outputs found
MSO906844 Supplemental Material - Supplemental material for White matter lesion location correlates with disability in relapsing multiple sclerosis
No full textSupplemental material, MSO906844 Supplemental Material for White matter lesion location correlates with disability in relapsing multiple sclerosis by Laura Gaetano, Baldur Magnusson, Petya Kindalova, Davorka Tomic, Diego Silva, Anna Altermatt, Stefano Magon, Nicole Müller-Lenke, Ernst-Wilhelm Radue, David Leppert, Ludwig Kappos, Jens Wuerfel, Dieter A Häring and Till Sprenger in Multiple Sclerosis Journal—Experimental, Translational and Clinical</p
sj-docx-1-msj-10.1177_13524585221078825 – Supplemental material for Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585221078825 for Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II by Jutta Gärtner, Stephen L Hauser, Amit Bar-Or, Xavier Montalban, Jeffrey A Cohen, Anne H Cross, Kumaran Deiva, Habib Ganjgahi, Dieter A Häring, Bingbing Li, Ratnakar Pingili, Krishnan Ramanathan, Wendy Su, Roman Willi, Bernd Kieseier and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585211055934 – Supplemental material for Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585211055934 for Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study by Jun-ichi Kira, Jin Nakahara, Denis V Sazonov, Takayoshi Kurosawa, Isao Tsumiyama, Roman Willi, Martin Zalesak, Ratnakar Pingili, Dieter A Häring, Krishnan Ramanathan, Bernd C Kieseier, Martin Merschhemke, Wendy Su and Takahiko Saida in Multiple Sclerosis Journal</p
sj-docx-3-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-3-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-8-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-8-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-11-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-11-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-pdf-10-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-pdf-10-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-5-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-5-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-2-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-2-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-9-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-9-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
- …
